ArticleAmerican journal of translational research2025
Efficacy and safety of Solifenacin combined with Mirabegron in treating overactive bladder in female patients following bladder instillation for bladder cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy and safety of Solifenacin combined with Mirabegron in treating overactive bladder (OAB) in female patients following bladder instillation for bladder cancer.
methodsA total of 62 female patients who developed OAB after undergoing transurethral resection of bladder tumor (TURBT) and subsequent intravesical chemotherapy with pirarubicin were enrolled from the Department of Urology at Guangzhou Twelfth People's Hospital. Patients were divided into two groups according to the method of treatment. The control group received Solifenacin, while the observation group received a combination of Solifenacin and Mirabegron. Pre- and post-treatment assessments included voiding frequency, Overactive Bladder Symptom Score (OABSS), urodynamic parameters, Incontinence Quality of Life (I-QOL) scores, and adverse reactions.
resultsBoth groups showed a significant reduction in 24-hour voiding frequency and average nocturia after treatment (P<0.05), with the observation group exhibiting a more pronounced decrease compared to the control group (P<0.05). Post-treatment evaluations revealed lower OABSS and maximum detrusor pressure during the storage phase in both groups, along with an increase in the initial sensation of bladder filling volume and maximum bladder capacity (P<0.05). The observation group demonstrated more significant improvements in OABSS and maximum detrusor pressure during the storage phase, as well as higher initial bladder sensation volume and maximum bladder capacity compared to the control group (P<0.01).
conclusionThe combination of Mirabegron and Solifenacin offers superior therapeutic effects in female patients with OAB following bladder instillation for bladder cancer, significantly improving patients' quality of life without adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.